Aeira

Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026

Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement...

Policy / Regulatory

NMPA Adds Metomidate, Lometomidate and Solriamfetol to Psychotropic Drug Schedule in Three‑Agency Regulatory Adjustment

Company Deals

NeuShen Therapeutics Closes Oversubscribed Series B Exceeding USD 80 Million to Accelerate Global CNS Pipeline

Policy / Regulatory

NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non‑Oral Dosage Forms

Company Drug

Hengrui Pharmaceuticals’ Oral GLP‑1R Agonist HRS‑7535 NDA Accepted by NMPA for Type 2 Diabetes, Joining China’s Incretin Race